Faquin William C, Wong Lawrence Q, Afrogheh Amir H, Ali Syed Z, Bishop Justin A, Bongiovanni Massimo, Pusztaszeri Marc P, VandenBussche Christopher J, Gourmaud Jolanta, Vaickus Louis J, Baloch Zubair W
Massachusetts General Hospital, Boston, Massachusetts.
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Cancer Cytopathol. 2016 Mar;124(3):181-7. doi: 10.1002/cncy.21631. Epub 2015 Oct 12.
Recent discussions have focused on redefining noninvasive follicular variant of papillary thyroid carcinoma (NI-FVPTC) as a neoplasm rather than a carcinoma. This study assesses the potential impact of such a reclassification on the implied risk of malignancy (ROM) for the diagnostic categories of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC).
The study consisted of consecutive fine-needle aspiration biopsy (FNAB) cases collected between January 1, 2013 and June 30, 2014 from 5 academic institutions. Demographic information, cytology diagnoses, and surgical pathology follow-up were recorded. The ROM was calculated with and without NI-FVPTC and was presented as a range: all cases (ie, overall risk of malignancy [OROM]) versus those with surgical follow-up only.
The FNAB cohort consisted of 6943 thyroid nodules representing 5179 women and 1409 men with an average age of 54 years (range, 9-94 years). The combined average ROM and OROM for the diagnostic categories of TBSRTC were as follows: nondiagnostic, 4.4% to 25.3%; benign, 0.9% to 9.3%; atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 12.1% to 31.2%; follicular neoplasm (FN), 21.8% to 33.2%; suspicious for malignancy (SM), 62.1% to 82.6%; and malignant, 75.9% to 99.1%. The impact of reclassifying NI-FVPTC on the ROM and OROM was most pronounced and statistically significant in the 3 indeterminate categories: the AUS/FLUS category had a decrease of 5.2% to 13.6%, the FN category had a decrease of 9.9% to 15.1%, and the SM category had a decrease of 17.6% to 23.4% (P < .05), whereas the benign and malignant categories had decreases of 0.3% to 3.5% and 2.5% to 3.3%, respectfully. The trend of the effect on the ROM and OROM was similar for all 5 institutions.
The results from this multi-institutional cohort indicate that the reclassification of NI-FVPTC will have a significant impact on the ROM for the 3 indeterminate categories of TBSRTC.
最近的讨论集中在将甲状腺乳头状癌的非侵袭性滤泡变体(NI-FVPTC)重新定义为一种肿瘤而非癌。本研究评估了这种重新分类对甲状腺细胞病理学报告贝塞斯达系统(TBSRTC)诊断类别中隐含恶性风险(ROM)的潜在影响。
该研究包括2013年1月1日至2014年6月30日期间从5家学术机构收集的连续细针穿刺活检(FNAB)病例。记录人口统计学信息、细胞学诊断和手术病理随访情况。计算有和没有NI-FVPTC时的ROM,并以范围表示:所有病例(即总体恶性风险[OROM])与仅接受手术随访的病例。
FNAB队列包括6943个甲状腺结节,代表5179名女性和1409名男性,平均年龄54岁(范围9 - 94岁)。TBSRTC诊断类别的综合平均ROM和OROM如下:无法诊断,4.4%至25.3%;良性,0.9%至9.3%;意义不明确的非典型性/意义不明确的滤泡性病变(AUS/FLUS),12.1%至31.2%;滤泡性肿瘤(FN),21.8%至33.2%;可疑恶性(SM),62.1%至82.6%;恶性,75.9%至99.1%。将NI-FVPTC重新分类对ROM和OROM的影响在3个不确定类别中最为显著且具有统计学意义:AUS/FLUS类别下降了5.2%至13.6%,FN类别下降了9.9%至15.1%,SM类别下降了17.6%至23.4%(P <.05),而良性和恶性类别分别下降了0.3%至3.5%和2.5%至3.3%。所有5家机构对ROM和OROM的影响趋势相似。
这个多机构队列的结果表明,NI-FVPTC的重新分类将对TBSRTC的3个不确定类别中的ROM产生重大影响。